{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T20:19:01Z","timestamp":1787170741592,"version":"build-2736575974"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,11,8]],"date-time":"2021-11-08T00:00:00Z","timestamp":1636329600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:p>\n                    <jats:bold>Introduction:<\/jats:bold>\n                    The use of teriparatide has been reported in children with hypoparathyroidism as an investigational physiologic replacement therapy.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Methods:<\/jats:bold>\n                    We aimed to retrospectively report our pediatric experience of bi-daily sub-cutaneous teriparatide. Results are presented as median (25th\u221275th quartile). As part of the routine follow-up of these patients with hypoparathyroidism, total calcium at H0 (i.e., just before injection) and H4 (i.e., 4 h after teriparatide injection) and other biomarker parameters were regularly assessed.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results:<\/jats:bold>\n                    At a median age of 10.7 (8.1\u201312.6) years, an estimated glomerular filtration rate (eGFR) of 110 (95\u2013118) mL\/min\/1.73 m\n                    <jats:sup>2<\/jats:sup>\n                    , calcium levels of 1.87 (1.81\u20131.96) mmol\/L and an age-standardized phosphate of 3.8 (2.5\u20134.9) SDS, teriparatide therapy was introduced in 10 patients at the dose of 1.1 (0.7\u20131.5) \u03bcg\/kg\/day (20 \u03bcg twice daily), with further adjustment depending on calcium levels. Six patients already displayed nephrocalcinosis. Severe side effects were reported in one child: two episodes of symptomatic hypocalcemia and one of iatrogenic hypercalcemia; one teenager displayed dysgueusia. Calcium levels at H0 did not significantly increase whilst calcium at H4 and phosphate levels significantly increased and decreased, respectively. After 12 months, eGFR, calcium and age-standardized phosphate levels were 108 (90\u2013122) mL\/min\/1.73 m\n                    <jats:sup>2<\/jats:sup>\n                    , 2.36 (2.23\u20132.48) mmol\/L, 0.5 (\u22120.1 to 1.5), and 68 (63\u201374) nmol\/L, respectively, with a significant decrease in phosphate levels (\n                    <jats:italic>p<\/jats:italic>\n                    = 0.01). Urinary calcium and calcium\/creatinine ratio remained stable; no nephrolithiasis was observed but two moderate nephrocalcinosis appeared.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusion:<\/jats:bold>\n                    Intermittent teriparatide therapy significantly improves calcium and phosphate control, without increasing calciuria. It appears to be safe and well-tolerated in children.\n                  <\/jats:p>","DOI":"10.3389\/fped.2021.764040","type":"journal-article","created":{"date-parts":[[2021,11,8]],"date-time":"2021-11-08T01:53:52Z","timestamp":1636336432000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Intermittent Bi-Daily Sub-cutaneous Teriparatide Administration in Children With Hypoparathyroidism: A Single-Center Experience"],"prefix":"10.3389","volume":"9","author":[{"given":"Julie","family":"Bernardor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sacha","family":"Flammier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Cabet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine","family":"Lemoine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Chapurlat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Molin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lia","family":"Bertholet-Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justine","family":"Bacchetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,11,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/nrdp.2017.55","article-title":"Hypoparathyroidism","volume":"3","author":"Mannstadt","year":"2017","journal-title":"Nat Rev Dis Primers."},{"key":"B2","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/j.beem.2018.09.007","article-title":"Clinical presentation and management of hypoparathyroidism","volume":"32","author":"Marcucci","year":"2018","journal-title":"Best Pract Res Clin Endocrinol Metab."},{"key":"B3","unstructured":""},{"key":"B4","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"Neer","year":"2001","journal-title":"N Engl J Med."},{"key":"B5","unstructured":""},{"key":"B6","doi-asserted-by":"publisher","first-page":"3389","DOI":"10.1210\/jc.2007-2552","article-title":"Effects of once versus twice-daily parathyroid hormone 1-34 therapy in children with hypoparathyroidism","volume":"93","author":"Winer","year":"2008","journal-title":"J Clin Endocrinol Metab."},{"key":"B7","doi-asserted-by":"publisher","first-page":"2680","DOI":"10.1210\/jc.2009-2464","article-title":"Long-term treatment of 12 children with chronic hypoparathyroidism: a randomized trial comparing synthetic human parathyroid hormone 1-34 versus calcitriol and calcium","volume":"95","author":"Winer","year":"2010","journal-title":"J Clin Endocrinol Metab."},{"key":"B8","doi-asserted-by":"publisher","first-page":"3308","DOI":"10.1210\/jc.2011-1359","article-title":"Long-term results of continuous subcutaneous recombinant PTH (1-34) infusion in children with refractory hypoparathyroidism","volume":"96","author":"Linglart","year":"2011","journal-title":"J Clin Endocrinol Metab."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1002\/jbmr.1627","article-title":"Daily parathyroid hormone 1-34 replacement therapy for hypoparathyroidism induces marked changes in bone turnover and structure","volume":"27","author":"Gafni","year":"2012","journal-title":"J Bone Miner Res."},{"key":"B10","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.jpeds.2014.04.060","article-title":"Effects of pump versus twice-daily injection delivery of synthetic parathyroid hormone 1-34 in children with severe congenital hypoparathyroidism","volume":"165","author":"Winer","year":"2014","journal-title":"J Pediatr."},{"key":"B11","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1515\/jpem-2013-0159","article-title":"Teriparatide (rhPTH) treatment in children with syndromic hypoparathyroidism","volume":"27","author":"Matarazzo","year":"2014","journal-title":"J Pediatr Endocrinol Metab."},{"key":"B12","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1002\/jbmr.2555","article-title":"Transient increased calcium and calcitriol requirements after discontinuation of human synthetic parathyroid hormone 1-34 (hPTH 1-34) replacement therapy in hypoparathyroidism","volume":"30","author":"Gafni","year":"2015","journal-title":"J Bone Miner Res."},{"key":"B13","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1159\/000479867","article-title":"Continuous subcutaneous recombinant parathyroid hormone (1-34) infusion in the management of childhood hypoparathyroidism associated with malabsorption","volume":"89","author":"Saraff","year":"2018","journal-title":"Horm Res Paediatr."},{"key":"B14","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.jpeds.2018.08.010","article-title":"Long-term parathyroid hormone 1-34 replacement therapy in children with hypoparathyroidism","volume":"203","author":"Winer","year":"2018","journal-title":"J Pediatr."},{"key":"B15","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/s12020-019-02128-z","article-title":"Teriparatide (rhPTH 1-34) treatment in the pediatric age: long-term efficacy and safety data in a cohort with genetic hypoparathyroidism","volume":"67","author":"Tuli","year":"2019","journal-title":"Endocrine"},{"key":"B16","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1210\/jc.2011-1908","article-title":"Synthetic human parathyroid hormone 1-34 replacement therapy: a randomized crossover trial comparing pump versus injections in the treatment of chronic hypoparathyroidism","volume":"97","author":"Winer","year":"2012","journal-title":"J Clin Endocrinol Metab."},{"key":"B17","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1007\/s00223-020-00665-8","article-title":"Hyperphosphatemia and chronic kidney disease: a major daily concern both in adults and in children","volume":"108","author":"Bacchetta","year":"2020","journal-title":"Calcif Tissue Int"},{"key":"B18","doi-asserted-by":"publisher","first-page":"2253","DOI":"10.1111\/apa.14907","article-title":"Assessment of mineral and bone biomarkers highlights a high frequency of hypercalciuria in asymptomatic healthy teenagers","volume":"108","author":"Bacchetta","year":"2019","journal-title":"Acta Paediatr."},{"key":"B19","first-page":"584","article-title":"Evaluation of bone and mineral disorders","volume":"5","author":"Ardeshirpour","year":"2007","journal-title":"Pediatr Endocrinol Rev."},{"key":"B20","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1258\/acb.2012.011274","article-title":"Paediatric reference values for the C-terminal fragment of fibroblast-growth factor-23, sclerostin, bone-specific alkaline phosphatase and isoform 5b of tartrate-resistant acid phosphatase","volume":"49","author":"Fischer","year":"2012","journal-title":"Ann Clin Biochem."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.2215\/CJN.01640309","article-title":"Measurement and estimation of GFR in children and adolescents","volume":"4","author":"Schwartz","year":"2009","journal-title":"Clin J Am Soc Nephrol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1210\/jc.2009-2057","article-title":"Height adjustment in assessing dual energy x-ray absorptiometry measurements of bone mass and density in children","volume":"95","author":"Zemel","year":"2010","journal-title":"J Clin Endocrinol Metab."},{"key":"B23","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s00223-010-9424-6","article-title":"Pharmacokinetics of teriparatide (rhPTH[1-34]) and calcium pharmacodynamics in postmenopausal women with osteoporosis","volume":"87","author":"Satterwhite","year":"2010","journal-title":"Calcif Tissue Int."},{"key":"B24","doi-asserted-by":"publisher","first-page":"4106","DOI":"10.1210\/jc.2015-2257","article-title":"The impact of hypoparathyroidism treatment on the kidney in children: long-term retrospective follow-up study","volume":"100","author":"Levy","year":"2015","journal-title":"J Clin Endocrinol Metab."},{"key":"B25","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.ando.2020.02.003","article-title":"Cardiovascular consequences of parathyroid disorders in adults","volume":"82","author":"Bollerslev","year":"2021","journal-title":"Ann Endocrinol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1007\/s00467-012-2347-x","article-title":"Phosphate is a vascular toxin","volume":"28","author":"Shroff","year":"2013","journal-title":"Pediatr Nephrol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"2300","DOI":"10.1210\/jc.2015-3909","article-title":"Presentation of hypoparathyroidism: etiologies and clinical features","volume":"101","author":"Shoback","year":"2016","journal-title":"J Clin Endocrinol Metab."},{"key":"B28","doi-asserted-by":"publisher","first-page":"153865","DOI":"10.1016\/j.metabol.2019.01.006","article-title":"Physiology of FGF23 and overview of genetic diseases associated with renal phosphate wasting","volume":"103","author":"Bacchetta","year":"2019","journal-title":"Metab Clin Exp"},{"key":"B29","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1080\/01926230601072301","article-title":"Defining a noncarcinogenic dose of recombinant human parathyroid hormone 1-84 in a 2-year study in Fischer 344 rats","volume":"34","author":"Jolette","year":"2006","journal-title":"Toxicol Pathol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1007\/s40265-015-0438-2","article-title":"Recombinant human parathyroid hormone (1-84): a review in hypoparathyroidism","volume":"75","author":"Kim","year":"2015","journal-title":"Drugs."},{"key":"B31","doi-asserted-by":"publisher","first-page":"523","DOI":"10.4158\/EP15936.OR","article-title":"AN OPEN-LABEL EXTENSION STUDY OF PARATHYROID HORMONE RHPTH(1-84) IN ADULTS WITH HYPOPARATHYROIDISM","volume":"22","author":"Lakatos","year":"2016","journal-title":"Endocr Pract."},{"key":"B32","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1002\/jbmr.5650070110","article-title":"Effects of continuous and intermittent administration and inhibition of resorption on the anabolic response of bone to parathyroid hormone","volume":"7","author":"Hock","year":"1992","journal-title":"J Bone Miner Res."}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2021.764040\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,8]],"date-time":"2021-11-08T01:53:54Z","timestamp":1636336434000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2021.764040\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,8]]},"references-count":32,"alternative-id":["10.3389\/fped.2021.764040"],"URL":"https:\/\/doi.org\/10.3389\/fped.2021.764040","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,8]]},"article-number":"764040"}}